ReShape Lifesciences Inc (RSLS) 銘柄情報

RSLS effective May 9,2025 a one for 25 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

$RSLS .3350 gap filled. On watch to see 👀 how it goes after the 1/25 <<< starting to look like another scam stock though with all the r/s'.

But even trash pays if you catch em' just right! lol

REshaping up nicely

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
Vagal Neuromodulation Offers a Novel Approach to Treating Diabetes and Hypoglycemia

Device Demonstrates the Ability to Modulate Glucose Levels Without Cardiac Side Effects, Overcoming a Key Limitation Of Conventional Vagal Stimulation Techniques

IRVINE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present pre-clinical data on its proprietary Diabetes Neuromodulation device in a poster presentation at the 12th Annual Minnesota Neuromodulation Symposium, being held in Minneapolis.

Poster Presentation Details:

Poster Title: Stimulation of the Posterior Sub-Diaphragmatic Vagal Trunk Reverses Insulin-Induced Severe Hypoglycemia in a Swine Model of Type 1 Diabetes Mellitus
Poster Number: 3308
Author: Jonathan J. Waataja, Ph.D., Director of Research at ReShape Lifesciences®
Session: Session B
Date: May 2, 2025
Time: 10:45 am -1:00 pm CT
“Hypoglycemia remains a significant barrier to effective diabetes management, contributing to severe health risks and reduced quality of life,” stated Dr. Waataja. “Our Diabetes Neuromodulation technology utilizes Hypoglycemia Vagus Nerve Stimulation (HVNS), targeting stimulation of the sub-diaphragmatic posterior vagus nerve (PVN) to rapidly increase blood glucose (BG) during hypoglycemic episodes. The ability to avoid cardiac side effects while effectively mitigating BG is critical for clinical viability. Unlike conventional vagal stimulation techniques, our targeted HVNS approach alters glucose levels without impacting heart rate, blood pressure or respiration, overcoming a key limitation of conventional vagal stimulation techniques. Also, sub-diaphragmatic stimulation does not affect speech, which is an obstacle to increasing desired therapeutic levels with conventional vagal stimulation. The pre-clinical data presented today paves the way for the continued development of our proprietary technology aimed at reducing dependence on injections and wearable glucose monitors, with the potential to dramatically improve quality of life for people with Type 1 or Type 2 diabetes.”

Designed to evaluate HVNS efficacy and off-target systemic effects in a Type 1 diabetic swine model, laparoscopic placement of an electrode on the PVN successfully increased blood glucose levels and glucagon secretion without impacting cardiac output. Following insulin-induced hypoglycemia (blood glucose

Easy, in @.39 out @.60 ---> I don't trust it to fly because of that gap down @.34 even though it was early am ... I'll take a little rather than risk>. GL

$RSLS: In at $0.59 ????

Howd u do that ???


GO $RSLS

$RSLS: Oooh....... nice move, now $0.54

I was busy eating breakfast.... missed that presser almost 38mins ago.

DANG IT !!!!!!


GO $RSLS

Out at .60 Thanks!

RSLS.......................................https://stockcharts.com/h-sc/ui?s=RSLS&p=W&b=5&g=0&id=p86431144783

LG! too bad they gapped it though, looking for exit.

rsls....................................................P/M

wow!

RSLS.............................................................p/m..........................weeeeeeeeeeeeee

Another after market party! +90% 🥳 💹

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

April 09, 2025

ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has signed an agreement with Haifa, Israel-based Motion Informatics to exclusively import and distribute their next-generation neuromuscular rehabilitation devices in the U.S. The flagship product, the Stimel-03, was showcased at the American Occupational Therapy Association 2025 Annual Conference and Expo, held April 3-5, 2025, in Philadelphia, PA.

“The signing of this agreement with Motion Informatics marks a significant milestone for ReShape as we expand and diversify into rehabilitation technology,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “This partnership presents a unique opportunity to bring cutting-edge, neurorehabilitation solutions to the U.S. market. We are particularly excited to distribute the FDA cleared and commercially available Stimel-03, a breakthrough system that integrates Functional Electrical Stimulation (FES), Neuromuscular Electrical Stimulation (NMES), and real-time electromyographic (EMG) biofeedback into a single, patient-responsive platform—redefining rehabilitation for patients recovering from stroke, injury, or surgery. Motion Informatics’ innovative devices align well with our commitment to improving patient outcomes, complementing our core competencies including commercialization of differentiated products including our Lap-Band® 2.0 FLEX, designed to improve patients’ quality of life while driving meaningful clinical and commercial impact.”

“This partnership accelerates Motion Informatics’ U.S. market strategy by combining ReShape Lifesciences’ commercial reach with our differentiated rehabilitation technologies,” added Gary Sagiv, Chief Executive Officer of Motion Informatics. “Our FDA-cleared Stimel-03 is changing clinical care using real-time EMG biofeedback and personalized electrical stimulation, making it easy to use in both clinic and home settings. Spatial StimelMD (SSMD), our next-generation platform and the first closed-loop neuromotor intelligence system combining AI-personalized neuromodulation, real-time EMG biofeedback, and augmented reality into one adaptive rehabilitation process. The SSMD reads a patient’s intent and generates cadenced stimulation to match, adapting in real-time based on performance, fatigue, and recovery—delivering precise care in clinics, at home, and through telemedicine. Together, these technologies position Motion Informatics and ReShape Lifesciences at the forefront of the neuromuscular rehabilitation market—delivering differentiated capabilities, validated outcomes, and a scalable path to global expansion. We are confident that ReShape is the ideal partner to distribute our products and expand their impact across the U.S.”

About Motion Informatics
Motion Informatics is pioneering next-generation neuromuscular rehabilitation by integrating AI-driven neuroinformatics, augmented reality (AR), and digital health into a seamless, adaptive therapeutic platform. The Company’s Spatial StimelMD (SSMD) leverages personalized real-time electrophysiological data, biofeedback-driven neuromodulation, and AI-optimized intervention protocols to dynamically personalize therapy, enhancing neuroplasticity, motor re-education, and functional recovery in conditions such as stroke, spinal cord injuries, and neuromuscular disorders. By fusing biomechanical modeling, predictive analytics, and remote neurorehabilitation, the Company is redefining precision rehabilitation, creating a highly scalable, intelligent, and data-driven ecosystem that bridges clinical and home-based care. This paradigmshift will establish AI-powered, fully autonomous, and continuously adaptive neuromuscular therapy, fundamentally transforming the future of digital healthcare.

About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.

https://ih.advfn.com/stock-market/NASDAQ/reshape-lifesciences-RSLS/stock-news/95816291/reshape-lifesciences-partners-with-motion-informa

$RSLS

hopped back in on the dip today.

RSLS..................................https://stockcharts.com/h-sc/ui?s=RSLS&p=W&b=5&g=0&id=p86431144783

and she’s off, lol.

but its trying to run. let’s see!

rsls has sudden …….

…

buying volume but now they are dumping it again, as if not wanting it to run.

$UAMY: Sounds good................

I'll get some at $0.25................... at $2.20 today is too high.

THANKS for the HEADSUP




GO $UAMY

here we go!

hopped back in since they have….

…

up to a year to r/s, i think the news was to temp drop this. lets see if im right.

grabbed 40’s.

Check UAMY, She is a keeper.

i got out for a nice ….

….

profit yday as these often do crap like that.

$RSLS: Out at $0.72

Secure what I have for now.

GO $RSLS

got .67 $RSLS in some @ .67 pic.twitter.com/hEKu48xz2b— THE FINAL COUNTDOWN (@THIS_TIME_X) April 2, 2025

$RSLS: Lets bounce to $1.20

I'll take that



GO $RSLS

What did they

OUCH...THAT HURTS THE DILUTION CHASERS

$RSLS The stockholders authorized the Board to amend the Company's Restated Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-2 to 1-for-250. Additionally, they approved the exercisability of 2,703,862 common stock purchase warrants and the issuance of up to 15,132,975 shares of common stock

$RSLS: Awesome.... gonna step in here at $0.63


Lets goooooooooooooooooooooooooooo

Only 10k shares


GO $RSLS

https://ih.advfn.com/stock-market/NASDAQ/reshape-lifesciences-RSLS/stock-news/95767669/form-8-k-current-report

Can retest the 52-week high of $30 at this rate

#DDAmanda Video: $RSLS: Gain: +317% #1 Early Alert Stock Finder



Z

HEPA Low Float Bio Tech under cash heavy short like RSLS ICCT

wish i had held longer, who knew? lol

Just sold but I might buy a few shares back for another afternoon run

i know you have me blocked but….

…

damn, you sure know how to pick’em! congrats to you and all that were in this one.

$RSLS: Got a few 6k here at $0.80

Lets gooooooooooooooooooooooooooooo


GO $RSLS

RSLS...........................................................................p/m

Saw the volume spike. Another ticker reverse splitting itself to almost no float at all.

https://ih.advfn.com/stock-market/NASDAQ/reshape-lifesciences-RSLS/stock-news/95634913/form-def-14a-other-definitive-proxy-statements

Wow

$1.80s hit a good quick flipper here

RSLS $1.25 Flippers paradise .90s the new king bottom

Offering at $2.30s best it's down enough. Back in .90s with stop loss .88

Offering at $2.33 and price already below $1.00

Opportunity for a relative easy move to $1.20-1.50 ?

RSLS $3.30 down -12% on news 700k floater ...Patent granted in Israel .. IRVINE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the State of Israel Patent Office for its Diabetes Neuromodulation technology. Patent Number 277949, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control Systems and Methods,” will provide protection until December 4, 2039. The Diabetes Neuromodulation system utilizes its proprietary vagus nerve block (vBloc™) technology platform, combined with vagus nerve stimulation, for the treatment of Type 2 diabetes, a prominent disorder associated with obesity.

Some RSLS buying on Friday 9/20 at PPS ~ .11 ,
Those shares now have a cost basis of 6.38 (post-split adjusted cost )
.11 X 58 = 6.38
The $5 dollar shares available (post split) on Monday were a better buy.
( looks like PPS held steady at about $8 in AH )
Maybe RSLS ---- > HIND ( new Co ) has some long term BioTech potential ?$
Daily volume on Monday was 7.7 M shares ! $
:popcorn:

post split plays rockin...bagholders always learn the hard way

So anyone that owned this before the split is under water.